Martin Flamant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martin Flamant has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Christos Chatziantoniou
INSERM UMR 702, Paris, France
3 shared publications - Jean-Claude Dussaule
Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) S 702, Hôpital Tenon, Assistance Publique–Hôpitaux de Paris (AP‐HP) Paris France
3 shared publications - Jean-Jacques Boffa
Tenon Hospital, Paris, France
3 shared publications Fadi Fakhouri
2 shared publications- Pierre-Louis Tharaux
Université Paris Cité, INSERM, PARCC, Paris, France
2 shared publications Dominique Chansel
From INSERM U489, Hôpital Tenon, and AP-HP (J.-C.D.), Department of Physiology, Hôpital St-Antoine, Paris, France
1 shared publication
Latest Publications
- Open Access
- 15 May 2005
- Published by EDP Sciences in médecine/sciences
- Vol. 21 (5) , 461-463
Les effets profibrosants des peptides vasoactifs dans le rein et les vaisseaux passent-ils par la transactivation du facteur de croissance épidermique (EGF)?
Mise en place des structures d'adhérence des cellules épithéliales. Nos premiers résultats montrent le rôle coopérateur des nectines dans la formation des jonctions adhérentes [10]. ◊ From cadherins to the quantification of cell adhesion RÉFÉRENCES 1.
- 15 May 2005
- Published by EDP Sciences in médecine/sciences
- Vol. 21 (5) , 461-463
Open AccessLes effets profibrosants des peptides vasoactifs dans le rein et les vaisseaux passent-ils par la transactivation du facteur de croissance épidermique (EGF)?
Mise en place des structures d'adhérence des cellules épithéliales. Nos premiers résultats montrent le rôle coopérateur des nectines dans la formation des jonctions adhérentes [10]. ◊ From cadherins to the quantification of cell adhesion RÉFÉRENCES 1.
- 1 November 2003
- Published by Wolters Kluwer Health in Hypertension
- Vol. 42 (5) , 937-944
Renal Effects of Omapatrilat and Captopril in Salt-Loaded, Nitric Oxide–Deficient Rats
Inhibition of nitric oxide synthases causes systemic hypertension and renal injury in rats. Our objective was to examine whether omapatrilat, a vasopeptidase inhibitor that inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase, could induce better regression of renal injury than ACE inhibitor alone. Ten groups of rats were studied. They were fed either a normal (0.8% NaCl) or a high (4% NaCl) sodium diet. Eight of these groups received N G -nitro- l -arginine methyl ester ( l -NAME, 20 mg · kg −1 · d −1 ) in their drinking water. After 4 weeks, 1 group on each diet was killed and considered the l -NAME group, whereas the others received l -NAME alone, captopril (200 mg · kg −1 · d −1 ) plus l -NAME, or omapatrilat (80 mg · kg −1 · d −1 ) plus l -NAME for 4 additional weeks. In rats receiving l -NAME alone for 8 weeks, the mortality rate was ≈90%, irrespective of the diet. In contrast, all rats survived in the captopril and the omapatrilat groups. In rats fed a normal-sodium diet, captopril and omapatrilat normalized systolic blood pressure and induced a complete regression of renal injury. Creatinine clearance and proteinuria were also normalized. In the high-sodium-diet groups, both treatments were less efficient: blood pressure remained elevated, and the regression of renal fibrosis was only partial. Although proteinuria decreased significantly with captopril or omapatrilat, creatinine clearance remained lower than in the controls. These results demonstrate that, in nitric oxide–deficient rats fed a normal-sodium diet, ACE and vasopeptidase inhibitors exhibit a marked renoprotective effect, whereas these treatments are less efficient in rats fed a high-sodium diet.
- 1 November 2003
- Published by Wolters Kluwer Health in Hypertension
- Vol. 42 (5) , 937-944
Renal Effects of Omapatrilat and Captopril in Salt-Loaded, Nitric Oxide–Deficient Rats
Inhibition of nitric oxide synthases causes systemic hypertension and renal injury in rats. Our objective was to examine whether omapatrilat, a vasopeptidase inhibitor that inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase, could induce better regression of renal injury than ACE inhibitor alone. Ten groups of rats were studied. They were fed either a normal (0.8% NaCl) or a high (4% NaCl) sodium diet. Eight of these groups received N G -nitro- l -arginine methyl ester ( l -NAME, 20 mg · kg −1 · d −1 ) in their drinking water. After 4 weeks, 1 group on each diet was killed and considered the l -NAME group, whereas the others received l -NAME alone, captopril (200 mg · kg −1 · d −1 ) plus l -NAME, or omapatrilat (80 mg · kg −1 · d −1 ) plus l -NAME for 4 additional weeks. In rats receiving l -NAME alone for 8 weeks, the mortality rate was ≈90%, irrespective of the diet. In contrast, all rats survived in the captopril and the omapatrilat groups. In rats fed a normal-sodium diet, captopril and omapatrilat normalized systolic blood pressure and induced a complete regression of renal injury. Creatinine clearance and proteinuria were also normalized. In the high-sodium-diet groups, both treatments were less efficient: blood pressure remained elevated, and the regression of renal fibrosis was only partial. Although proteinuria decreased significantly with captopril or omapatrilat, creatinine clearance remained lower than in the controls. These results demonstrate that, in nitric oxide–deficient rats fed a normal-sodium diet, ACE and vasopeptidase inhibitors exhibit a marked renoprotective effect, whereas these treatments are less efficient in rats fed a high-sodium diet.
- 1 January 2002
- Published by EDP Sciences in Biologie Aujourd'hui
- Vol. 196 (4) , 275-280
Peptides vasoactifs et développement de la sclérose rénale : apports de la transgenèse
- 1 January 2002
- Published by EDP Sciences in Biologie Aujourd'hui
- Vol. 196 (4) , 275-280
Peptides vasoactifs et développement de la sclérose rénale : apports de la transgenèse
- 1 January 2002
- Vol. 196 (4) , 275-80
[Vasoactive peptides and the development of renal sclerosis: contribution of transgenes].
Vasoactive peptides are implied in the development of renal sclerosis as evidenced by the efficiency of their antagonists in preventing glomerulosclerosis of experimental and human nephropathies. Genetically engineered models provide a new approach to investigate the mechanisms of the renal profibrotic actions of angiotensin II and endothelin. Overexpression of the human angiotensinogen and renin genes in rats induces renal sclerosis independently of changes in systemic hemodynamics. The same results are observed when the endothelin-1 gene is overexpressed in mice. Transgenic mice harboring the luciferase gene under the control of the collagen I-alpha 2 chain promoter (procol alpha 2[1]) and made hypertensive by induction of nitric oxide (NO) deficiency were used to study the renal profibrotic actions of vasoactive peptides. In this strain of mice, luciferase activity is an early index of renal fibrosis. Luciferase activity was increased in preglomerular arterioles and glomeruli when mice were deficient in NO. The pharmacological blockade of angiotensin II and endothelin prevented the development of renal sclerosis without modifying blood pressure. Moreover, when the endothelin receptor antagonist was administered after the development of renal fibrosis, preformed glomerulosclerosis partially regressed. Acute administration of vasoactive peptides and TGF-beta in transgenic procol alpha 2[1] mice showed that the angiotensin II activation of collagen I gene requires participation and/or cooperation of endothelin and TGF-beta. Recent data suggest that the profibrotic actions of vasoactive peptides also need the activation of EGF receptor, ERK and rho kinase pathways in renal and vascular cells.
- 1 January 2002
- Vol. 196 (4) , 275-80
[Vasoactive peptides and the development of renal sclerosis: contribution of transgenes].
Vasoactive peptides are implied in the development of renal sclerosis as evidenced by the efficiency of their antagonists in preventing glomerulosclerosis of experimental and human nephropathies. Genetically engineered models provide a new approach to investigate the mechanisms of the renal profibrotic actions of angiotensin II and endothelin. Overexpression of the human angiotensinogen and renin genes in rats induces renal sclerosis independently of changes in systemic hemodynamics. The same results are observed when the endothelin-1 gene is overexpressed in mice. Transgenic mice harboring the luciferase gene under the control of the collagen I-alpha 2 chain promoter (procol alpha 2[1]) and made hypertensive by induction of nitric oxide (NO) deficiency were used to study the renal profibrotic actions of vasoactive peptides. In this strain of mice, luciferase activity is an early index of renal fibrosis. Luciferase activity was increased in preglomerular arterioles and glomeruli when mice were deficient in NO. The pharmacological blockade of angiotensin II and endothelin prevented the development of renal sclerosis without modifying blood pressure. Moreover, when the endothelin receptor antagonist was administered after the development of renal fibrosis, preformed glomerulosclerosis partially regressed. Acute administration of vasoactive peptides and TGF-beta in transgenic procol alpha 2[1] mice showed that the angiotensin II activation of collagen I gene requires participation and/or cooperation of endothelin and TGF-beta. Recent data suggest that the profibrotic actions of vasoactive peptides also need the activation of EGF receptor, ERK and rho kinase pathways in renal and vascular cells.